Vincenzo Silani

List of Publications by Year in Descending Order

326 papers	15,292 citations	65 h-index	114 g-index
372 ext. papers	18,261 ext. citations	5.8 avg, IF	5.96 L-index

#	Paper	IF	Citations
326	Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis.. *Neuron*, **2022**,	13.9	8
325	Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis.. *Npj Genomic Medicine*, **2022**, 7, 8	6.2	4
324	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS.. *Science Translational Medicine*, **2022**, 14, eabj0264	17.5	4
323	One-Year Cognitive Follow-Up of COVID-19 Hospitalized Patients.. *European Journal of Neurology*, **2022**,	6	4
322	Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB-SINdem).. *Neurological Sciences*, **2022**, 1	3.5	
321	Quantum Biology Research Meets Pathophysiology and Therapeutic Mechanisms: A Biomedical Perspective. *Quantum Reports*, **2022**, 4, 148-172	2.1	1
320	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. *Nature Genetics*, **2021**, 53, 1636-1648	36.3	19
319	Prolonged cognitive deficits after COVID-19. *Journal of the Neurological Sciences*, **2021**, 429, 119804	3.2	78
318	expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed. *Brain Communications*, **2021**, 3, fcab236	4.5	0
317	ROLE OF RISK SCORING SYSTEMS IN PREDICTING LIFE EXPECTANCY AFTER CAROTID ENDARTERECTOMY IN ASYMPTOMATIC PATIENTS. *Journal of Vascular Surgery*, **2021**,	3.5	2
316	Compensating for verbal-motor deficits in neuropsychological assessment in movement disorders: sensitivity and specificity of the ECAS in Parkinson☹ and Huntington☹ diseases. *Neurological Sciences*, **2021**, 42, 4997-5006	3.5	0
315	Testing olfactory dysfunction in acute and recovered COVID-19 patients: a single center study in Italy. *Neurological Sciences*, **2021**, 42, 2183-2189	3.5	1
314	Genetic characterization of a cohort with familial parkinsonism and cognitive-behavioral syndrome: A Next Generation Sequencing study. *Parkinsonism and Related Disorders*, **2021**, 84, 82-90	3.6	1
313	Influence of contralateral carotid artery occlusions on short- and long-term outcomes of carotid artery stenting: a retrospective single-center analysis and review of literature. *International Angiology*, **2021**, 40, 87-96	2.2	
312	It won☹ happen to me! Psychosocial factors influencing risk perception for respiratory infectious diseases: A scoping review. *Applied Psychology: Health and Well-Being*, **2021**, 13, 835-852	6.8	5
311	The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial. *Brain*, **2021**, 144, 2635-2647	11.2	10
310	Association between renin-angiotensin-aldosterone system inhibitors and risk of dementia: A meta-analysis. *Pharmacological Research*, **2021**, 166, 105515	10.2	2

309	Epileptic Capgras-Like Delusions in a Patient with Right Frontal Meningioma: Case Report. *Case Reports in Neurology*, **2021**, 13, 284-288	1	
308	Unilateral freezing of gait or "magnetic feet phenomenon" caused by ischemic lesion involving fronto-striatal networks. *Neurological Sciences*, **2021**, 42, 3467-3469	3.5	
307	A Computational Fluid-Structure Interaction Study for Carotids With Different Atherosclerotic Plaques. *Journal of Biomechanical Engineering*, **2021**, 143,	2.1	3
306	Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. *Frontiers in Neuroscience*, **2021**, 15, 679199	5.1	9
305	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. *Neuron*, **2021**, 109, 448-460.e4	13.9	20
304	Next-generation sequencing application to investigate skeletal muscle channelopathies in a large cohort of Italian patients. *Neuromuscular Disorders*, **2021**, 31, 336-347	2.9	4
303	A susceptibility-weighted imaging qualitative score of the motor cortex may be a useful tool for distinguishing clinical phenotypes in amyotrophic lateral sclerosis. *European Radiology*, **2021**, 31, 1281-1289	8	2
302	Cerebrospinal fluid phosphorylated neurofilament heavy chain and chitotriosidase in primary lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 221-223	5.5	2
301	The Effect of SMN Gene Dosage on ALS Risk and Disease Severity. *Annals of Neurology*, **2021**, 89, 686-697	9.4	2
300	Amyotrophic lateral sclerosis phenotypes significantly differ in terms of magnetic susceptibility properties of the precentral cortex. *European Radiology*, **2021**, 31, 5272-5280	8	5
299	Long-Lasting Cognitive Abnormalities after COVID-19. *Brain Sciences*, **2021**, 11,	3.4	26
298	Counterfactual thinking in psychiatric and neurological diseases: A scoping review. *PLoS ONE*, **2021**, 16, e0246388	3.7	0
297	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2021**, 22, 276-286	3.6	5
296	Attachment, Personality and Locus of Control: Psychological Determinants of Risk Perception and Preventive Behaviors for COVID-19. *Frontiers in Psychology*, **2021**, 12, 634012	3.4	8
295	Genetic and epigenetic disease modifiers in an Italian family expressing ALS, FTD or PD clinical phenotypes. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2021**, 1-7	3.6	0
294	Exosome microRNAs in Amyotrophic Lateral Sclerosis: A Pilot Study. *Biomolecules*, **2021**, 11,	5.9	2
293	SUMOylation Regulates TDP-43 Splicing Activity and Nucleocytoplasmic Distribution. *Molecular Neurobiology*, **2021**, 58, 5682-5702	6.2	1
292	A preliminary comparison between ECAS and ALS-CBS in classifying cognitive-behavioural phenotypes in a cohort of non-demented amyotrophic lateral sclerosis patients. *Journal of Neurology*, **2021**, 1	5.5	0

291	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. *JAMA Neurology*, **2021**, 78, 1236-1248	17.2	5
290	The contribution of the Italian residents in neurology to the COVID-19 crisis: admirable generosity but neurological training remains their priority. *Neurological Sciences*, **2021**, 42, 4425-4431	3.5	
289	Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**,	5.5	9
288	Association of Clinically Evident Eye Movement Abnormalities With Motor and Cognitive Features in Patients With Motor Neuron Disorders. *Neurology*, **2021**, 97, e1835-e1846	6.5	1
287	Structural MRI Signatures in Genetic Presentations of the Frontotemporal Dementia/Motor Neuron Disease Spectrum. *Neurology*, **2021**, 97, e1594-e1607	6.5	3
286	Progression of cognitive and behavioral disturbances in motor neuron diseases assessed using standard and computer-based batteries. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2021**, 22, 223-236	3.6	1
285	Impaired recognition of disgust in amyotrophic lateral sclerosis is related to basal ganglia involvement. *NeuroImage: Clinical*, **2021**, 32, 102803	5.3	0
284	A nationwide survey on clinical neurophysiology education in Italian schools of specialization in neurology. *Neurological Sciences*, **2021**, 1	3.5	
283	Identification of the Raman Salivary Fingerprint of Parkinson© Disease Through the Spectroscopic-Computational Combinatory Approach. *Frontiers in Neuroscience*, **2021**, 15, 704963	5.1	3
282	Progression of brain functional connectivity and frontal cognitive dysfunction in ALS. *NeuroImage: Clinical*, **2020**, 28, 102509	5.3	5
281	An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19 (NEUROCOVID). *Neurological Sciences*, **2020**, 41, 1355-1359	3.5	27
280	Rising evidence for neurological involvement in COVID-19 pandemic. *Neurological Sciences*, **2020**, 41, 1339-1341	3.5	23
279	Advance care planning and mental capacity in ALS: a current challenge for an unsolved matter. *Neurological Sciences*, **2020**, 41, 2997-2998	3.5	1
278	Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis. *Scientific Reports*, **2020**, 10, 10175	4.9	21
277	Telepsychotherapy: a leaflet for psychotherapists in the age of COVID-19. A review of the evidence. *Counselling Psychology Quarterly*, **2020**, 1-16	2.5	32
276	Reprogramming fibroblasts and peripheral blood cells from a C9ORF72 patient: A proof-of-principle study. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 4051-4060	5.6	5
275	Structural MRI outcomes and predictors of disease progression in amyotrophic lateral sclerosis. *NeuroImage: Clinical*, **2020**, 27, 102315	5.3	6
274	Cervical transverse MRI in ALS diagnosis and possible link to VEGF and MMP9 single nucleotide polymorphisms. Case Report. *SN Comprehensive Clinical Medicine*, **2020**, 2, 814-816	2.7	

273	Focus on the heterogeneity of amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2020**, 21, 485-495	3.6	14
272	Primary lateral sclerosis: consensus diagnostic criteria. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 373-377	5.5	59
271	Toward a marker of upper motor neuron impairment in amyotrophic lateral sclerosis: A fully automatic investigation of the magnetic susceptibility in the precentral cortex. *European Journal of Radiology*, **2020**, 124, 108815	4.7	9
270	Genetics of primary lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration* , **2020**, 21, 28-34	3.6	5
269	CSF angiogenin levels in amyotrophic lateral Sclerosis-Frontotemporal dementia spectrum. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2020**, 21, 63-69	3.6	3
268	Chronic stress induces formation of stress granules and pathological TDP-43 aggregates in human ALS fibroblasts and iPSC-motoneurons. *Neurobiology of Disease*, **2020**, 145, 105051	7.5	18
267	TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients. *Brain Communications*, **2020**, 2, fcaa142	4.5	24
266	Clinical features and outcomes of the flail arm and flail leg and pure lower motor neuron MND variants: a multicentre Italian study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 1001-1003	5.5	6
265	Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene. *Cell Reports*, **2020**, 33, 108456	10.6	6
264	New technologies and Amyotrophic Lateral Sclerosis - Which step forward rushed by the COVID-19 pandemic?. *Journal of the Neurological Sciences*, **2020**, 418, 117081	3.2	19
263	Fiberoptic endoscopic evaluation of swallowing in early-to-advanced stage Huntington© disease. *Scientific Reports*, **2020**, 10, 15242	4.9	5
262	Carotid artery stenting is safe and effective for symptomatic patients with acute coronary syndrome. *Catheterization and Cardiovascular Interventions*, **2020**, 96, 129-135	2.7	1
261	Aortic arch types and postoperative outcomes after carotid artery stenting in asymptomatic and symptomatic patients. *International Angiology*, **2020**, 39, 485-491	2.2	2
260	Comparative Analysis of and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of Positive Patients. *Frontiers in Neuroscience*, **2019**, 13, 485	5.1	22
259	Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS). *BMJ Open*, **2019**, 9, e028486	3	26
258	PON1 is a disease modifier gene in amyotrophic lateral sclerosis: association of the Q192R polymorphism with bulbar onset and reduced survival. *Neurological Sciences*, **2019**, 40, 1469-1473	3.5	8
257	Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. *Neurology*, **2019**, 92, e1610-e1623	6.5	74
256	Three-year outcomes after carotid artery revascularization: Gender-related differences. *Vascular*, **2019**, 27, 459-467	1.3	3

255	TDP-43 and NOVA-1 RNA-binding proteins as competitive splicing regulators of the schizophrenia-associated TNIK gene. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2019**, 1862, 194413	6	2
254	A Novel Approach for Investigating Parkinson© Disease Personality and Its Association With Clinical and Psychological Aspects. *Frontiers in Psychology*, **2019**, 10, 2265	3.4	1
253	Inter-Species Differences in Regulation of the Progranulin-Sortilin Axis in TDP-43 Cell Models of Neurodegeneration. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	2
252	A Novel Mutation of Causing Adult-Onset Alexander Disease. *Frontiers in Neurology*, **2019**, 10, 1124	4.1	0
251	Neurochemical biomarkers in amyotrophic lateral sclerosis. *Current Opinion in Neurology*, **2019**, 32, 747-757	7	12
250	Heterogeneous brain FDG-PET metabolic patterns in patients with C9orf72 mutation. *Neurological Sciences*, **2019**, 40, 515-521	3.5	10
249	Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis. *Muscle and Nerve*, **2019**, 59, 531-536	3.4	20
248	Response to the commentary "The effect of C9orf72 intermediate repeat expansions in neurodegenerative and autoimmune diseases" by Biasiotto G and Zanella I. *Multiple Sclerosis and Related Disorders*, **2019**, 27, 79-80	4	
247	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 157-164	5.5	113
246	Does metabolic syndrome influence short and long term durability of carotid endarterectomy and stenting?. *Diabetes/Metabolism Research and Reviews*, **2019**, 35, e3084	7.5	8
245	Sexuality and intimacy in ALS: systematic literature review and future perspectives. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 712-719	5.5	2
244	Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. *European Journal of Neurology*, **2018**, 25, 861-868	6	19
243	Characterization of the c9orf72 GC-rich low complexity sequence in two cohorts of Italian and Turkish ALS cases. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2018**, 19, 426-431	3.6	2
242	Understanding the use of NIV in ALS: results of an international ALS specialist survey. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2018**, 19, 331-341	3.6	20
241	Is diabetes a marker of higher risk after carotid revascularization? Experience from a single centre. *Diabetes and Vascular Disease Research*, **2018**, 15, 314-321	3.3	7
240	Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2018**, 67, 21-22	5.6	4
239	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. *Neuron*, **2018**, 97, 1268-1283.e6	13.9	296
238	The Complex Interplay Between Depression/Anxiety and Executive Functioning: Insights From the ECAS in a Large ALS Population. *Frontiers in Psychology*, **2018**, 9, 450	3.4	11

237	Genotypic and Phenotypic Heterogeneity in Amyotrophic Lateral Sclerosis **2018**, 279-295		1
236	No C9orf72 repeat expansion in patients with primary progressive multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2018**, 25, 192-195	4	7
235	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. *Neurology*, **2018**, 90, e22-e30	6.5	106
234	Do Women Have a Higher Risk of Adverse Events after Carotid Revascularization? **2018**,		1
233	The Arrows and Colors Cognitive Test (ACCT): A new verbal-motor free cognitive measure for executive functions in ALS. *PLoS ONE*, **2018**, 13, e0200953	3.7	9
232	Cognitive-behavioral longitudinal assessment in ALS: the Italian Edinburgh Cognitive and Behavioral ALS screen (ECAS). *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2018**, 19, 387-395	3.6	22
231	Motor neuron differentiation of iPSCs obtained from peripheral blood of a mutant TARDBP ALS patient. *Stem Cell Research*, **2018**, 30, 61-68	1.6	15
230	ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. *Neurobiology of Aging*, **2018**, 71, 266.e1-266.e10	5.6	44
229	Genetic analysis of the SOD1 and C9ORF72 genes in Hungarian patients with amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2017**, 53, 195.e1-195.e5	5.6	15
228	An eye-tracking controlled neuropsychological battery for cognitive assessment in neurological diseases. *Neurological Sciences*, **2017**, 38, 595-603	3.5	7
227	An eye-tracker controlled cognitive battery: overcoming verbal-motor limitations in ALS. *Journal of Neurology*, **2017**, 264, 1136-1145	5.5	15
226	Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. *Annals of Neurology*, **2017**, 81, 837-848	9.4	20
225	Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. *Science Translational Medicine*, **2017**, 9,	17.5	74
224	Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. *Annals of Neurology*, **2017**, 82, 139-146	9.4	58
223	Inefficient skeletal muscle oxidative function flanks impaired motor neuron recruitment in Amyotrophic Lateral Sclerosis during exercise. *Scientific Reports*, **2017**, 7, 2951	4.9	10
222	Adiponectin levels in the serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients: possible influence on neuroinflammation?. *Journal of Neuroinflammation*, **2017**, 14, 85	10.1	3
221	Poly(GP) proteins are a useful pharmacodynamic marker for -associated amyotrophic lateral sclerosis. *Science Translational Medicine*, **2017**, 9,	17.5	128
220	Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2017**, 18, 153-174	3.6	371

219	July 2017 ENCALS statement on edaravone. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2017**, 18, 471-474	3.6	31
218	Use of Noninvasive Ventilation During Feeding Tube Placement. *Respiratory Care*, **2017**, 62, 1474-1484	2.1	11
217	The role of de novo mutations in the development of amyotrophic lateral sclerosis. *Human Mutation*, **2017**, 38, 1534-1541	4.7	10
216	Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial). *BMJ Open*, **2017**, 7, e015434	3	12
215	Safety and Efficacy of the New Micromesh-Covered Stent CGuard in Patients Undergoing Carotid Artery Stenting: Early Experience From a Single Centre. *European Journal of Vascular and Endovascular Surgery*, **2017**, 54, 681-687	2.3	21
214	The synaptic function of parkin. *Brain*, **2017**, 140, 2265-2272	11.2	31
213	Factors predicting survival in ALS: a multicenter Italian study. *Journal of Neurology*, **2017**, 264, 54-63	5.5	68
212	The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. *Neurological Sciences*, **2017**, 38, 83-91	3.5	10
211	X-linked Parkinsonism with Intellectual Disability caused by novel mutations and somatic mosaicism in RAB39B gene. *Parkinsonism and Related Disorders*, **2017**, 44, 142-146	3.6	18
210	Cognitive-constructivist Approach in Medical Settings: The Use of Personal Meaning Questionnaire for Neurological PatientsÕPersonality Investigation. *Frontiers in Psychology*, **2017**, 8, 582	3.4	2
209	Neuropsychiatric Burden in HuntingtonÕs Disease. *Brain Sciences*, **2017**, 7,	3.4	48
208	Brain-Computer Interface for Clinical Purposes: Cognitive Assessment and Rehabilitation. *BioMed Research International*, **2017**, 2017, 1695290	3	41
207	The emerging picture of ALS: a multisystem, not only a "motor neuron disease. *Archives Italiennes De Biologie*, **2017**, 155, 99-109	1.1	15
206	Therapy in Amyotrophic Lateral Sclerosis (ALS): an unexpected evolving scenario. *Archives Italiennes De Biologie*, **2017**, 155, 118-130	1.1	14
205	Cerebral microbleeds: A new presenting feature of chromosome 22q11.2 deletion syndrome. *Journal of the Neurological Sciences*, **2016**, 368, 300-3	3.2	3
204	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. *Nature Genetics*, **2016**, 48, 1043-8	36.3	328
203	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. *Nature Genetics*, **2016**, 48, 1037-42	36.3	149
202	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. *Nature Communications*, **2016**, 7, 11253	17.4	126

201	You stole my food! Eating alterations in frontotemporal dementia. *Neurocase*, **2016**, 22, 400-9	0.8	12
200	The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS). *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2016**, 17, 489-498	3.6	72
199	Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. *JAMA Neurology*, **2016**, 73, 812-20	17.2	40
198	Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. *Acta Neuropathologica Communications*, **2016**, 4, 47	7.3	96
197	Phenotypic Modulation and Neuroprotective Effects of Olfactory Ensheathing Cells: a Promising Tool for Cell Therapy. *Stem Cell Reviews and Reports*, **2016**, 12, 224-34	6.4	18
196	Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 810-6	5.5	43
195	Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus. *Frontiers in Immunology*, **2016**, 7, 5	8.4	22
194	Cognitive assessment in Amyotrophic Lateral Sclerosis by means of P300-Brain Computer Interface: a preliminary study. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2016**, 17, 473-481	3.6	11
193	MRI abnormalities found 1 year prior to symptom onset in a case of Creutzfeldt-Jakob disease. *Journal of Neurology*, **2016**, 263, 597-9	5.5	9
192	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2016**, 17, 404-13	3.6	65
191	TUBA4A gene analysis in sporadic amyotrophic lateral sclerosis: identification of novel mutations. *Journal of Neurology*, **2015**, 262, 1376-8	5.5	31
190	The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. *Alzheimer's and Dementia*, **2015**, 11, 1407-1416	1.2	126
189	From transcriptomic to protein level changes in TDP-43 and FUS loss-of-function cell models. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2015**, 1849, 1398-410	6	30
188	Dysregulated IGFBP5 expression causes axon degeneration and motoneuron loss in diabetic neuropathy. *Acta Neuropathologica*, **2015**, 130, 373-87	14.3	18
187	CHCHD10 mutations in Italian patients with sporadic amyotrophic lateral sclerosis. *Brain*, **2015**, 138, e372	11.2	49
186	A review of options for treating sialorrhea in amyotrophic lateral sclerosis. *Respiratory Care*, **2015**, 60, 446-54	2.1	49
185	Novel mutations support a role for Profilin 1 in the pathogenesis of ALS. *Neurobiology of Aging*, **2015**, 36, 1602.e17-27	5.6	67
184	Counterfactual Thinking Deficit in Huntington's Disease. *PLoS ONE*, **2015**, 10, e0126773	3.7	6

183	Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3) has a key role in the mitochondrial dysfunction induced by mutant huntingtin. *Human Molecular Genetics*, **2015**, 24, 6530-9	5.6	10
182	Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy. *Neurological Sciences*, **2015**, 36, 751-7	3.5	8
181	Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. *Science*, **2015**, 347, 1436-41	33.3	642
180	Editorial on the original article entitled "Genetic validation of a therapeutic target in a mouse model of ALS" published in the Science Translational Medicine on August 6, 2014. *Annals of Translational Medicine*, **2015**, 3, S27	3.2	
179	A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. *Journal of Medical Genetics*, **2014**, 51, 419-24	5.8	96
178	A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. *Human Molecular Genetics*, **2014**, 23, 2220-31	5.6	95
177	Resting state functional connectivity alterations in primary lateral sclerosis. *Neurobiology of Aging*, **2014**, 35, 916-25	5.6	30
176	Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?. *Lancet Neurology, The*, **2014**, 13, 1127-1138	24.1	189
175	Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. *Neuron*, **2014**, 84, 324-31	13.9	229
174	Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. *Neuron*, **2014**, 83, 1043-50	13.9	232
173	C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis. *Annals of Neurology*, **2014**, 76, 120-33	9.4	61
172	Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features. *Neurobiology of Aging*, **2014**, 35, 408-17	5.6	29
171	C9orf72 repeat expansions are restricted to the ALS-FTD spectrum. *Neurobiology of Aging*, **2014**, 35, 936.e13-7	5.6	24
170	Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2014**, 15, 344-50	3.6	55
169	Intrahemispheric and interhemispheric structural network abnormalities in PLS and ALS. *Human Brain Mapping*, **2014**, 35, 1710-22	5.9	64
168	Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. *Journal of Hypertension*, **2014**, 32, 1888-97	1.9	55
167	Parkin regulates kainate receptors by interacting with the GluK2 subunit. *Nature Communications*, **2014**, 5, 5182	17.4	35
166	An old woman with pressure ulcer, rigidity, and opisthotonus: never forget tetanus!. *Lancet, The*, **2014**, 384, 2266	40	6

165	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. *Journal of Hypertension*, **2014**, 32, 1741-50	1.9	31
164	Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study. *Neurobiology of Aging*, **2014**, 35, 2420.e13-4	5.6	14
163	Amyotrophic Lateral Sclerosis: Genotypes and Phenotypes **2014**, 179-192		1
162	Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options. *BMC Neurology*, **2013**, 13, 84	3.1	67
161	Charles Bonnet syndrome: two case reports and review of the literature. *Journal of Neurology*, **2013** , 260, 1180-6	5.5	20
160	Androgen-dependent impairment of myogenesis in spinal and bulbar muscular atrophy. *Acta Neuropathologica*, **2013**, 126, 109-21	14.3	32
159	ELAV proteins along evolution: back to the nucleus?. *Molecular and Cellular Neurosciences*, **2013**, 56, 447-58	4	46
158	Dysphagia in amyotrophic lateral sclerosis: prevalence and clinical findings. *Acta Neurologica Scandinavica*, **2013**, 128, 397-401	3.8	67
157	Oligoclonal bands in the cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated mutations. *Journal of Neurology*, **2013**, 260, 85-92	5.5	19
156	Neurorescue effects and stem properties of chorionic villi and amniotic progenitor cells. *Neuroscience*, **2013**, 234, 158-72	3.9	23
155	Screening of the PFN1 gene in sporadic amyotrophic lateral sclerosis and in frontotemporal dementia. *Neurobiology of Aging*, **2013**, 34, 1517.e9-10	5.6	31
154	Analysis of hnRNPA1, A2/B1, and A3 genes in patients with amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2013**, 34, 2695.e11-2	5.6	24
153	Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2013**, 14, 397-405	3.6	47
152	Biocompatible fluorescent nanoparticles for in vivo stem cell tracking. *Nanotechnology*, **2013**, 24, 245603	3.4	26
151	Cobalamin as a regulator of serum and cerebrospinal fluid levels of normal prions. *Journal of Clinical Neuroscience*, **2013**, 20, 134-8	2.2	5
150	Pilot trial of clenbuterol in spinal and bulbar muscular atrophy. *Neurology*, **2013**, 80, 2095-8	6.5	37
149	The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. *European Journal of Human Genetics*, **2013**, 21, 102-8	5.3	159
148	Vascular and parenchymal lesions along with enhanced neurogenesis characterize the brain of asymptomatic stroke-prone spontaneous hypertensive rats. *Journal of Hypertension*, **2013**, 31, 1618-28	1.9	4

147	Ubiquilin 2 mutations in Italian patients with amyotrophic lateral sclerosis and frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 183-7	5.5	58
146	Carotid artery stenting in patients with acute coronary syndrome: a possible primary therapy for symptomatic carotid stenosis. *Journal of Endovascular Therapy*, **2013**, 20, 546-51	2.5	8
145	No evidence of cardiomyopathy in spinal and bulbar muscular atrophy. *Acta Neurologica Scandinavica*, **2013**, 128, e30-2	3.8	12
144	Wake-up stroke and TIA due to paradoxical embolism during long obstructive sleep apnoeas: a cross-sectional study. *Thorax*, **2013**, 68, 97-104	7.3	32
143	Defining the role of the Bcl-2 family proteins in Huntington disease. *Cell Death and Disease*, **2013**, 4, e772	9.8	24
142	Dose dependent side effect of superparamagnetic iron oxide nanoparticle labeling on cell motility in two fetal stem cell populations. *PLoS ONE*, **2013**, 8, e78435	3.7	29
141	Extramotor damage is associated with cognition in primary lateral sclerosis patients. *PLoS ONE*, **2013**, 8, e82017	3.7	28
140	Cognitive assessment of executive functions using brain computer interface and eye-tracking. *EAI Endorsed Transactions on Ambient Systems*, **2013**, 13, e4	0	7
139	EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. *European Journal of Neurology*, **2012**, 19, 360-75	6	617
138	Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients. *Muscle and Nerve*, **2012**, 45, 200-8	3.4	31
137	Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: implications for reparative therapy in Parkinson disease. *Apoptosis: an International Journal on Programmed Cell Death*, **2012**, 17, 289-304	5.4	26
136	TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells. *Journal of Biological Chemistry*, **2012**, 287, 15635-47	5.4	190
135	Prevalence of Huntington disease gene CAG repeat alleles in sporadic amyotrophic lateral sclerosis patients. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2012**, 13, 265-9		13
134	Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. *Nature*, **2012**, 488, 499-503	50.4	416
133	Mutational analysis of VCP gene in familial amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2012**, 33, 630.e1-2	5.6	14
132	ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling. *Neurobiology of Aging*, **2012**, 33, 1847.e15-21	5.6	24
131	C9ORF72 repeat expansion in a large Italian ALS cohort: evidence of a founder effect. *Neurobiology of Aging*, **2012**, 33, 2528.e7-14	5.6	64
130	Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson disease. *International Journal of Nanomedicine*, **2012**, 7, 435-47	7.3	21

129	The use of P300-based BCIs in amyotrophic lateral sclerosis: from augmentative and alternative communication to cognitive assessment. *Brain and Behavior*, **2012**, 2, 479-98	3.4	45
128	Validating the Neuro VR-Based Virtual Version of the Multiple Errands Test: Preliminary Results. *Presence: Teleoperators and Virtual Environments*, **2012**, 21, 31-42	2.9	44
127	Molecular signatures of amyotrophic lateral sclerosis disease progression in hind and forelimb muscles of an SOD1(G93A) mouse model. *Antioxidants and Redox Signaling*, **2012**, 17, 1333-50	8.4	45
126	Longitudinal tracking of human fetal cells labeled with super paramagnetic iron oxide nanoparticles in the brain of mice with motor neuron disease. *PLoS ONE*, **2012**, 7, e32326	3.7	25
125	Intracerebroventricular administration of human umbilical cord blood cells delays disease progression in two murine models of motor neuron degeneration. *Rejuvenation Research*, **2011**, 14, 623-39	3.6	38
124	Intracerebral haemorrhage, a possible presentation in Churg-Strauss syndrome: case report and review of the literature. *Journal of the Neurological Sciences*, **2011**, 301, 107-11	3.2	16
123	No association of DPP6 with amyotrophic lateral sclerosis in an Italian population. *Neurobiology of Aging*, **2011**, 32, 966-7	5.6	22
122	Mutational analysis of TARDBP in neurodegenerative diseases. *Neurobiology of Aging*, **2011**, 32, 2096-9	5.6	36
121	Ultrastructural mitochondrial abnormalities in patients with sporadic amyotrophic lateral sclerosis. *Archives of Neurology*, **2011**, 68, 1612-3		8
120	The combined use of Brain Computer Interface and Eye-Tracking technology for cognitive assessment in Amyotrophic Lateral Sclerosis **2011**,		12
119	VPS54 genetic analysis in ALS Italian cohort. *European Journal of Neurology*, **2011**, 18, e41-2	6	4
118	Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington© disease. *Movement Disorders*, **2011**, 26, 130-7	7	42
117	Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. *Muscle and Nerve*, **2011**, 43, 189-95	3.4	50
116	Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2011**, 156B, 285-90	3.5	120
115	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. *Annals of Neurology*, **2011**, 70, 964-73	9.4	144
114	The survival of motor neuron (SMN) protein interacts with the mRNA-binding protein HuD and regulates localization of poly(A) mRNA in primary motor neuron axons. *Journal of Neuroscience*, **2011**, 31, 3914-25	6.6	161
113	Endovascular management of symptomatic cerebral malperfusion due to carotid dissection after type A aortic dissection repair. *Vascular and Endovascular Surgery*, **2011**, 45, 641-5	1.4	12
112	Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 1239-43	5.5	65

111	The diagnosis of Amyotrophic lateral sclerosis in 2010. *Archives Italiennes De Biologie*, **2011**, 149, 5-27	1.1	20
110	RNA-binding proteins and RNA metabolism: a new scenario in the pathogenesis of Amyotrophic lateral sclerosis. *Archives Italiennes De Biologie*, **2011**, 149, 83-99	1.1	21
109	Genetics of familial Amyotrophic lateral sclerosis. *Archives Italiennes De Biologie*, **2011**, 149, 65-82	1.1	64
108	Amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD). *Archives Italiennes De Biologie*, **2011**, 149, 39-56	1.1	27
107	Amyotrophic lateral sclerosis: applications of stem cells - an update. *Stem Cells and Cloning: Advances and Applications*, **2010**, 3, 145-56	2.6	5
106	Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. *Neurology*, **2010**, 75, 619-25	6.5	78
105	Mutations of FUS gene in sporadic amyotrophic lateral sclerosis. *Journal of Medical Genetics*, **2010**, 47, 190-4	5.8	131
104	Mutant Huntingtin induces activation of the Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3). *Cell Death and Disease*, **2010**, 1, e7	9.8	21
103	The present and the future of neuroimaging in amyotrophic lateral sclerosis. *American Journal of Neuroradiology*, **2010**, 31, 1769-77	4.4	97
102	Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial. *Cytotherapy*, **2010**, 12, 50-9	4.8	31
101	Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. *Archives of Neurology*, **2010**, 67, 849-54		95
100	Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. *Cell Transplantation*, **2010**, 19, 203-17	4	117
99	COGNITIVE FUNCTION UNDER EXPOSURE TO HYPOBARIC HYPOXIA AT ALTITUDE: DATA FROM THE HIGHCARE PROJECT: PP.4.136. *Journal of Hypertension*, **2010**, 28, e89	1.9	
98	A13 Mutant huntingtin induces activation of Bcl-2/adenovirus E1B 19-kDa interacting protein (BNIP3). *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, A4.3-A4	5.5	
97	Metalloproteinase alterations in the bone marrow of ALS patients. *Journal of Molecular Medicine*, **2010**, 88, 553-64	5.5	26
96	Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. *Lancet Neurology, The*, **2010**, 9, 986-94	24.1	171
95	Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson© disease. *Brain Research*, **2010**, 1311, 12-27	3.7	112
94	Paraoxonase gene mutations in amyotrophic lateral sclerosis. *Annals of Neurology*, **2010**, 68, 102-7	9.4	56

93	Free insulin-like growth factor (IGF)-1 and IGF-binding proteins-2 and -3 in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients. *European Journal of Neurology*, **2010**, 17, 398-404	6	18
92	EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases. *European Journal of Neurology*, **2010**, 17, 526-e20	6	62
91	Protein aggregation and defective RNA metabolism as mechanisms for motor neuron damage. *CNS and Neurological Disorders - Drug Targets*, **2010**, 9, 285-96	2.6	33
90	Stem cells in amyotrophic lateral sclerosis: motor neuron protection or replacement?. *CNS and Neurological Disorders - Drug Targets*, **2010**, 9, 314-24	2.6	19
89	Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort. *Neurology*, **2009**, 73, 1180-5	6.5	116
88	IPLEX and the telephone game: the difficulty in separating myth from reality on the internet. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2009**, 10, 182-4		3
87	Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 9004-9	11.5	149
86	High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. *Human Mutation*, **2009**, 30, 688-94	4.7	155
85	TDP-43 is recruited to stress granules in conditions of oxidative insult. *Journal of Neurochemistry*, **2009**, 111, 1051-61	6	347
84	Huntington© disease: the current state of research with peripheral tissues. *Experimental Neurology*, **2009**, 219, 385-97	5.7	125
83	Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2009**, 10, 378-83		67
82	Increased Il-8 Levels in the Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis. *European Journal of Inflammation*, **2009**, 7, 39-44	0.3	3
81	Obstructive Sleep Apnea Syndrome: A Cause of Acute Delirium. *Journal of Clinical Sleep Medicine*, **2009**, 05, 569-570	3.1	15
80	Stem cell transplantation in multiple sclerosis: safety and ethics. *Journal of the Neurological Sciences*, **2008**, 265, 116-21	3.2	12
79	Post-transcriptional regulation of neuro-oncological ventral antigen 1 by the neuronal RNA-binding proteins ELAV. *Journal of Biological Chemistry*, **2008**, 283, 7531-41	5.4	50
78	Re: What is next in ALS clinical trials?. *Neurology*, **2008**, 70, 1365-6; author reply 1365-6	6.5	1
77	Molecular and phenotypical characterization of human amniotic fluid cells and their differentiation potential. *Bio-Medical Materials and Engineering*, **2008**, 18, 183-185	1	3
76	Re: What is next in ALS clinical trials?. *Neurology*, **2008**, 70, 1366; author reply 1366-7	6.5	1

75	Dysgraphia in patients with primary lateral sclerosis: a speech-based rehearsal deficit?. *Behavioural Neurology*, **2008**, 19, 169-75	3	11
74	Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. *Neurogenetics*, **2008**, 9, 33-40	3	94
73	Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington© disease patients. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2007**, 144B, 574-7	3.5	122
72	Age at onset in sod1-mediated amyotrophic lateral sclerosis shows familiality. *Neurogenetics*, **2007**, 8, 235-6	3	14
71	Phase II/III randomized trial of TCH346 in patients with ALS. *Neurology*, **2007**, 69, 776-84	6.5	93
70	Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2007**, 8, 217-23		88
69	Induction of neurotrophin expression via human adult mesenchymal stem cells: implication for cell therapy in neurodegenerative diseases. *Cell Transplantation*, **2007**, 16, 41-55	4	83
68	Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2007**, 8, 195-213		130
67	A role for the ELAV RNA-binding proteins in neural stem cells: stabilization of Msi1 mRNA. *Journal of Cell Science*, **2006**, 119, 1442-52	5.3	67
66	Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington© disease subjects. *Cell Death and Differentiation*, **2006**, 13, 2068-78	12.7	72
65	Molecular and phenotypic characterization of human amniotic fluid cells and their differentiation potential. *Cell Research*, **2006**, 16, 329-36	24.7	156
64	Apoptosis induced by proteasome inhibition in human myoblast cultures. *European Journal of Histochemistry*, **2006**, 50, 109-18	2.1	4
63	Neuro-glial differentiation of human bone marrow stem cells in vitro. *Experimental Neurology*, **2005** , 193, 312-25	5.7	164
62	EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. *European Journal of Neurology*, **2005**, 12, 921-38	6	211
61	Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. *Muscle and Nerve*, **2005**, 32, 541-4	3.4	88
60	Cell-replacement therapy with stem cells in neurodegenerative diseases. *Current Neurovascular Research*, **2004**, 1, 283-9	1.8	17
59	Stem cell therapy for neurodegenerative diseases: the issue of transdifferentiation. *Stem Cells and Development*, **2004**, 13, 121-31	4.4	25
58	Stem-cell therapy for amyotrophic lateral sclerosis. *Lancet, The*, **2004**, 364, 200-2	40	87

57	Stem Cell Therapy for ALS: Hope and RealityA discussion paper from the Executive of the European ALS Consortium. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases*, **2003**, 4, 8-10		14
56	Stem cells in the treatment of amyotrophic lateral sclerosis (ALS). *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases*, **2002**, 3, 173-81		13
55	Amyotrophic lateral sclerosis care in Italy: a nationwide study in neurological centers. *Journal of the Neurological Sciences*, **2001**, 191, 145-50	3.2	44
54	Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. *Journal of the Neurological Sciences*, **2001**, 191, 25-33	3.2	162
53	Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. *Science*, **2001**, 293, 493-8	33.3	1044
52	Superoxide dismutase gene mutations in Italian patients with familial and sporadic amyotrophic lateral sclerosis: identification of three novel missense mutations. *Neuromuscular Disorders*, **2001**, 11, 404-10	2.9	36
51	Human developing motor neurons as a tool to study ALS. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases*, **2001**, 2 Suppl 1, S69-76		4
50	Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases*, **2001**, 2, 159-64		67
49	The pathogenesis of ALS: implications for treatment strategies. *Neurologia I Neurochirurgia Polska*, **2001**, 35, 25-39	1	2
48	Motor neurones in culture as a model to study ALS. *Journal of Neurology*, **2000**, 247 Suppl 1, I28-36	5.5	12
47	A tentative interpretation of electromyographic regional differences in bulbar-and limb-onset ALS. *Neurology*, **2000**, 54, 536-7	6.5	1
46	Bartolomeo Panizza and the discovery of the brain's visual center. *Archives of Neurology*, **2000**, 57, 1642-8		12
45	Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. *Neuromuscular Disorders*, **2000**, 10, 391-7	2.9	86
44	Macular preservation with bilateral visual field defect caused by embolic occlusion of the posterior cerebral arteries. *Journal of Neurology*, **1999**, 246, 55-7	5.5	
43	Motor neurone metabolism. *Journal of the Neurological Sciences*, **1999**, 169, 161-9	3.2	13
42	Isolation and characterization of a novel transcript embedded within HIRA, a gene deleted in DiGeorge syndrome. *Molecular Genetics and Metabolism*, **1999**, 67, 227-35	3.7	17
41	Honesty and hope: announcement of diagnosis in ALS. *Neurology*, **1999**, 53, S37-9; discussion S40-2	6.5	18
40	Nutritional management in amyotrophic lateral sclerosis: a worldwide perspective. *Journal of Neurology*, **1998**, 245 Suppl 2, S13-9; discussion S29	5.5	49

39	A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. *Neurology*, **1998**, 51, 583-6	6.5	295
38	Immunomagnetic isolation of human developing motor neurons. *NeuroReport*, **1998**, 9, 1143-7	1.7	10
37	UFD1L, a developmentally expressed ubiquitination gene, is deleted in CATCH 22 syndrome. *Human Molecular Genetics*, **1997**, 6, 259-65	5.6	75
36	Expression study of survival motor neuron gene in human fetal tissues. *Biochemical and Molecular Medicine*, **1997**, 61, 102-6		27
35	Morphological differentiation of astroglial progenitor cells from EGF-responsive neurospheres in response to fetal calf serum, basic fibroblast growth factor, and retinol. *Cell Transplantation*, **1996**, 5, 179-89	4	23
34	Ras p21 protein promotes survival and differentiation of human embryonic neural crest-derived cells. *Neuroscience*, **1996**, 73, 1121-7	3.9	16
33	Clinical and pathological features in hydrocarbon-induced parkinsonism. *Annals of Neurology*, **1996**, 40, 922-5	9.4	33
32	Deletion analysis of the simple tandem repeat loci physically linked to the spinal muscular atrophy locus. *Human Mutation*, **1996**, 7, 198-201	4.7	5
31	cDNA characterization and chromosomal mapping of two human homologues of the Drosophila dishevelled polarity gene. *Human Molecular Genetics*, **1996**, 5, 953-8	5.6	50
30	Human homologue sequences to the Drosophila dishevelled segment-polarity gene are deleted in the DiGeorge syndrome. *American Journal of Human Genetics*, **1996**, 58, 722-9	11	37
29	Human substantia nigra in vitro as a bioassay for neurotrophic molecules of clinical significance. *Advances in Neurology*, **1996**, 69, 253-62		1
28	Postzygotic instability of the myotonic dystrophy p[AGC] in repeat supported by larger expansions in muscle and reduced amplifications in sperm. *Journal of Neurology*, **1995**, 242, 379-83	5.5	12
27	Identification of multiple transcribed sequences from the spinal muscular atrophy region of human chromosome 5. *Biochemical and Biophysical Research Communications*, **1995**, 206, 294-301	3.4	5
26	Molecules with neurotrophic effects on the human developing mesencephalic dopaminergic neurons. *Journal of Neural Transmission Supplementum*, **1995**, 45, 287-96		
25	High conservation of the trinucleotide [CTG]n repeat at the myotonic dystrophy locus in nonhuman primates. *Human Evolution*, **1994**, 9, 315-321		
24	Development of dopaminergic neurons in the human mesencephalon and in vitro effects of basic fibroblast growth factor treatment. *Experimental Neurology*, **1994**, 128, 59-76	5.7	30
23	NGF-response of EGF-dependent progenitor cells obtained from human sympathetic ganglia. *NeuroReport*, **1994**, 5, 2085-9	1.7	7
22	Ganglioside GM1 expression during human spinal cord and neural crest development. *NeuroReport*, **1993**, 4, 767-70	1.7	10

21	Acquisition of the Immunophenotype by Human Adrenal Cells. *Journal of Neural Transplantation & Plasticity*, **1992**, 3, 211-212		78
20	Human fetal brain beta-nerve growth factor cDNA: molecular cloning of 5′ and 3′ untranslated regions. *Neuroscience Letters*, **1991**, 127, 117-20	3.3	2
19	Beta-nerve growth factor (beta-NGF) mRNA expression in the parkinsonian adrenal gland. *Experimental Neurology*, **1991**, 113, 166-70	5.7	8
18	Adrenal medulla autograft in 3 parkinsonian patients: results using two different approaches. *Progress in Brain Research*, **1990**, 82, 677-82	2.9	4
17	Effect of nerve growth factor in adrenal autografts in parkinsonism. *Annals of Neurology*, **1990**, 27, 341-2	9.4	108
16	Detection of beta-nerve growth factor mRNA in the human fetal brain. *Brain Research*, **1990**, 518, 337-41	3.7	11
15	cDNA sequence of human beta-NGF. *Nucleic Acids Research*, **1990**, 18, 4020	20.1	11
14	Human neuronal cell viability demonstrated in culture after cryopreservation. *Brain Research*, **1988**, 473, 169-74	3.7	43
13	Cryopreservation of human fetal adrenal medullary cells. *Brain Research*, **1988**, 454, 383-6	3.7	9
12	Surgical lesions, parkinsonism, and brain graft operations. *Lancet, The*, **1988**, 2, 346	40	15
11	Characterization of purified populations of human fetal chromaffin cells: considerations for grafting in parkinsonian patients. *Progress in Brain Research*, **1988**, 78, 551-7	2.9	1
10	Human Fetal Adrenal Medulla for Transplantation in Parkinsonian Patients. *Annals of the New York Academy of Sciences*, **1987**, 495, 771-773	6.5	4
9	Neuroimmunology of human fetal brain in tissue culture. *International Journal of Developmental Neuroscience*, **1985**, 3, 451-451	2.7	
8	Manifesting carrier of x-linked Duchenne muscular dystrophy. *Journal of the Neurological Sciences*, **1981**, 49, 455-63	3.2	14
7	Metabolic impairment and membrane abnormality in red cells from Huntington's disease. *Journal of the Neurological Sciences*, **1980**, 47, 93-103	3.2	33
6	Erythrocyte spectrofluorometric abnormalities in Duchenne patients and carriers. A new approach to carrier detection. *Acta Neurologica Scandinavica*, **1979**, 59, 262-9	3.8	10
5	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. *SSRN Electronic Journal*,	1	2
4	Mutations in the SPTLC1 gene are a cause of juvenile amyotrophic lateral sclerosis that may be amenable to serine supplementation		2

3	Neuroimaging in the Management of Motor Neuron Diseases199-211	
2	Genome-wide study of DNA methylation in Amyotrophic Lateral Sclerosis identifies differentially methylated loci and implicates metabolic, inflammatory and cholesterol pathways	1
1	Management of Amyotrophic Lateral Sclerosis283-310	1